GSK乙肝新药叩门上市,小核酸商业化拐点已至

药创新
Mar 02

一个新的治疗时代,正在全面到来。撰文丨大眼怪2月26日,GSK宣布:日本厚生劳动省已正式受理其反义寡核苷酸(ASO)药物Bepirovirsen的上市申请,适应症为成人慢性乙型肝炎。这一消息在医药界激起的涟漪,远超一般的NDA受理公告——它被视为小核酸药物迈入“主流慢病时代”的历史性信号。继小分子与抗体药物之后,小核酸药物凭借独特的基因调控机制、长效给药以及能够攻克传统不可成药靶点的潜力,正强势...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10